Cotton Mouton Diagnostics Ltd (CMD), a Cardiff based diagnostics company, has developed a rapid and novel point-of-need analytical platform based on proprietary intellectual property. This technology has initially been applied to the rapid and sensitive detection of bacterial endotoxins in the large and expanding pharmaceutical quality control market.
Subsequently the technology will target an un-met need in the diagnosis and monitoring of biomarkers at point-of-care (PoC) where it will compete in the growing $16bn PoC testing market.
The technology is readily applicable to pre-hospital care, an under-utilised area of medical diagnostics, where for many clinical conditions rapid-diagnosis and treatment is critical if favourable patient outcomes are to be delivered.
CMD Ltd has filed three patent families protecting its nano-sensing technology, the first of which has been granted in USA, Europe and China.